Coffee Roasting and Glucose Tolerance

University of Copenhagen

Status: Completed

Conditions: Oral Glucose Tolerance

Treatments: Other: LIR; Other: DAR; Other: CTR

Study type: Interventional

Funder types: Other

Identifiers

NCT02417519

M217

Details and patient eligibility

About

Chlorogenic acid (CGA) in coffee may lower the postprandial glucose response. CGA is destroyed by dark roasting. In a controlled crossover trial, 11 healthy fasted volunteers consumed 300 mL of either light (LIR) or dark (DAR) roasted coffee, or water, followed 30 min later by a 75-g oral glucose tolerance test (OGTT). Plasma glukose and insulin, appetite, and plasma and urine metabolic profiles will be analysed. The primary aim is to investigate whether roasting affects the postprandial glucose area under the curve (AUC).

Full description

Epidemiologic evidence suggests that coffee consumption is associated with a lower risk of type 2 diabetes. Coffee contains caffeine and several other components that may modulate glucose regulation. The chlorogenic acids (CGA) in coffee have been indicated as constituents that may help to normalize the acute glucose response after a carbohydrate challenge. The aim of this study was to investigate whether two coffee beverages that differ in CGA content due to different roasting degrees will affect glucose regulation differently.

In a controlled crossover trial, 11 healthy fasted volunteers consumed 300 mL of either light roasted (LIR) or dark roasted (DAR) coffee, or water, followed 30 min later by a 75-g oral glucose tolerance test (OGTT). Blood samples were drawn at baseline, 30, 60 and 120 min. Differences in glucose and insulin responses and insulin sensitivity index (ISI) were analyzed. The CGA and caffeine contents in the coffees were analyzed using UPLC-MS/MS.

Enrollment: 11 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Body mass index (BMI) of 18.0-30.0 kg/m2 and with no known diseases

Exclusion criteria

• systemic infections,
• psychiatric or metabolic disorders,
• known food allergies or intolerances related to the products used in the study (e.g. dairy or gluten),
• ongoing or former drug abuse,
• high intake of alcohol (defined as a weekly intake of >7 units for women and > 14 units for men),
• pregnancy or ongoing planning of pregnancy,
• vegetarianism or veganism,
• participation in other scientific studies during the study period, and
• blood donation during - or in the month leading up to - the study period

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

11 participants in 6 patient groups

Sequence A

Experimental group

Description:

The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance A was DAR-LIR-CTR

Treatment:

Other: CTR

Other: DAR

Other: LIR

Sequence B

Experimental group

Description:

The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance B was DAR-CTR-LIR

Treatment:

Other: CTR

Other: DAR

Other: LIR

Sequance C

Experimental group

Description:

The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance C was LIR-DAR-CTR

Treatment:

Other: CTR

Other: DAR

Other: LIR

Sequence D

Experimental group

Description:

The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance D was LIR-CTR-DAR

Treatment:

Other: CTR

Other: DAR

Other: LIR

Sequence E

Experimental group

Description:

The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance E was CTR-DAR-LIR

Treatment:

Other: CTR

Other: DAR

Other: LIR

Sequence F

Experimental group

Description:

The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance F was CTR-LIR-DAR

Treatment:

Other: CTR

Other: DAR

Other: LIR